secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001104659-25-120789
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Phase 2 TOIVA study: 73% of patients improved; plans FDA discussions for Breakthrough Therapy
--------------------------------------------------------------------------------

- 73% (11/15) improved on Overall cVM-IGA at Week 12; 67% rated "Much Improved" or "Very Much Improved".
- Statistical significance on multiple endpoints, including Overall cVM-IGA (p<0.001) and PGI-C (p<0.001).
- QTORIN rapamycin generally well-tolerated; no drug-related SAEs; most common AE application site erythema (25%).
- Company plans near-term FDA discussions for Breakthrough Therapy Designation and Phase 3 pivotal study.
- Potential first FDA-approved therapy for cutaneous venous malformations affecting >75,000 patients in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/0001104659-25-120789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/tm2533458d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-120789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer